Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alexion Pharmaceuticals

Criteria

Inclusion Criteria:

• Healthy individuals 25 to 55 years of age with documented vaccination with MCV4.

Exclusion Criteria:

• Abnormal renal or liver function.

• History of meningococcal disease.

• History of Guillain-Barre syndrome.

• Known infection with HIV or Hepatitis B or C.